The invention is directed to compositions comprising a modified dextran and to uses thereof for the treatment of wounds in a subject or for delivering a protein, an olignonucleotide, a pharmaceutical agent, or a mixture thereof to a subject. The modified dextran in the compositions can form hydrogels via crosslinking.

The invention is directed to compositions comprising a modified dextran and to uses thereof for the treatment of wounds in a subject or for delivering a protein, an olignonucleotide, a pharmaceutical agent, or a mixture thereof to a subject. The modified dextran in the compositions can form hydrogels via crosslinking.

A polyelectrolyte complex includes nanofibers. The nanofibers include at least one polycationic component and at least one polyanionic component. The nanofibers have a diameter in a range of 20-100 nm. A process for preparing the complex, a method of using the complex, a kit which includes the complex, and a method of inhibiting loss of blood from a wound site by applying the complex to the wound site are also provided.

A polyelectrolyte complex includes nanofibers. The nanofibers include at least one polycationic component and at least one polyanionic component. The nanofibers have a diameter in a range of 20-100 nm. A process for preparing the complex, a method of using the complex, a kit which includes the complex, and a method of inhibiting loss of blood from a wound site by applying the complex to the wound site are also provided.

Compositions are disclosed herein comprising dextran that comprises (i) 87-93 wt % glucose linked at positions 1 and 6; (ii) 0.1-1.2 wt % glucose linked at positions 1 and 3; (iii) 0.1-0.7 wt % glucose linked at positions 1 and 4; (iv) 7.7-8.6 wt % glucose linked at positions 1, 3 and 6; and (v) about 0.4-1.7 wt % glucose linked at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. Aqueous forms of this composition have enhanced viscosity profiles. Further disclosed are methods of using compositions comprising dextran, such as increasing the viscosity of an aqueous composition. Enzymatic reactions for producing dextran are also disclosed.

Compositions are disclosed herein comprising dextran that comprises (i) 87-93 wt % glucose linked at positions 1 and 6; (ii) 0.1-1.2 wt % glucose linked at positions 1 and 3; (iii) 0.1-0.7 wt % glucose linked at positions 1 and 4; (iv) 7.7-8.6 wt % glucose linked at positions 1, 3 and 6; and (v) about 0.4-1.7 wt % glucose linked at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. Aqueous forms of this composition have enhanced viscosity profiles. Further disclosed are methods of using compositions comprising dextran, such as increasing the viscosity of an aqueous composition. Enzymatic reactions for producing dextran are also disclosed.

Disclosed herein are compositions comprising at least one alpha-glucan graft copolymer derivative compound (e.g., ether or ester) having a degree of substitution (DoS) up to about 3.0. The precursors of these derivative compounds are graft copolymers that comprise a dextran backbone and alpha-glucan side chains. At least about 30% of the glycosidic linkages of the alpha-glucan side chains are alpha-1,3 glycosidic linkages. Further disclosed are methods of producing graft copolymer derivatives, as well as their use in various applications and products.

A drug-loaded implanted medical device (10) and a preparation method therefor. The drug-loaded implanted medical device (10) comprises a device body (100), a hydrophilic coating layer (200) loaded on the device body (100), and crystalline drug particles (300) loaded on the hydrophilic coating layer (200). The hydrophilic coating layer (200) comprises a graft polymer containing a photo-crosslinked group. The medical device (10) uses a hydrophilic coating layer (200) as a carrier, effectively avoiding the risk of embolism, encouraging the crystalline drug particles to fall off, and helping to achieve a target tissue concentration. The invention can also effectively increase the anchoring effect between the carrier and the device, and reduce toxicity.

A drug-loaded implanted medical device (10) and a preparation method therefor. The drug-loaded implanted medical device (10) comprises a device body (100), a hydrophilic coating layer (200) loaded on the device body (100), and crystalline drug particles (300) loaded on the hydrophilic coating layer (200). The hydrophilic coating layer (200) comprises a graft polymer containing a photo-crosslinked group. The medical device (10) uses a hydrophilic coating layer (200) as a carrier, effectively avoiding the risk of embolism, encouraging the crystalline drug particles to fall off, and helping to achieve a target tissue concentration. The invention can also effectively increase the anchoring effect between the carrier and the device, and reduce toxicity.

Polymeric compositions are provided that include a poly(ethylene glycol), a viscoelastic polymer, and an antioxidant, where, in polymerized form, the compositions have a refractive index of about 1.30 to about 1.40. Methods of synthesizing the compositions are also provided and include the steps of heating an amount of water; adding a buffering agent to the water to form a buffer solution; mixing a poly(ethylene glycol) and a viscoelastic polymer into the buffer solution to form a reactive mixture; adding a plurality of antioxidant particles to the reactive mixture; and removing suspended gas bubbles from the reactive mixture. Methods of preventing oxidative damage to an eye lens of a subject are further provided and include administering the foregoing polymeric compositions to the eye lens of the subject.